首页> 美国卫生研究院文献>British Medical Journal >Comparison of treatment effects between animal experiments and clinical trials: systematic review
【2h】

Comparison of treatment effects between animal experiments and clinical trials: systematic review

机译:动物实验和临床试验的治疗效果比较:系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective To examine concordance between treatment effects in animal experiments and clinical trials. >Study design Systematic review. >Data sources Medline, Embase, SIGLE, NTIS, Science Citation Index, CAB, BIOSIS. >Study selection Animal studies for interventions with unambiguous evidence of a treatment effect (benefit or harm) in clinical trials: head injury, antifibrinolytics in haemorrhage, thrombolysis in acute ischaemic stroke, tirilazad in acute ischaemic stroke, antenatal corticosteroids to prevent neonatal respiratory distress syndrome, and bisphosphonates to treat osteoporosis. >Review methods Data were extracted on study design, allocation concealment, number of randomised animals, type of model, intervention, and outcome. >Results Corticosteroids did not show any benefit in clinical trials of treatment for head injury but did show a benefit in animal models (pooled odds ratio for adverse functional outcome 0.58, 95% confidence interval 0.41 to 0.83). Antifibrinolytics reduced bleeding in clinical trials but the data were inconclusive in animal models. Thrombolysis improved outcome in patients with ischaemic stroke. In animal models, tissue plasminogen activator reduced infarct volume by 24% (95% confidence interval 20% to 28%) and improved neurobehavioural scores by 23% (17% to 29%). Tirilazad was associated with a worse outcome in patients with ischaemic stroke. In animal models, tirilazad reduced infarct volume by 29% (21% to 37%) and improved neurobehavioural scores by 48% (29% to 67%). Antenatal corticosteroids reduced respiratory distress and mortality in neonates whereas in animal models respiratory distress was reduced but the effect on mortality was inconclusive (odds ratio 4.2, 95% confidence interval 0.85 to 20.9). Bisphosphonates increased bone mineral density in patients with osteoporosis. In animal models the bisphosphonate alendronate increased bone mineral density compared with placebo by 11.0% (95% confidence interval 9.2% to 12.9%) in the combined results for the hip region. The corresponding treatment effect in the lumbar spine was 8.5% (5.8% to 11.2%) and in the combined results for the forearms (baboons only) was 1.7% (−1.4% to 4.7%). >Conclusions Discordance between animal and human studies may be due to bias or to the failure of animal models to mimic clinical disease adequately.
机译:>目的以检查动物实验和临床试验中治疗效果之间的一致性。 >研究设计系统评价。 >数据来源:Medline,Embase,SIGLE,NTIS,科学引文索引,CAB,BIOSIS。 >研究选择在临床试验中具有明确证据表明具有治疗效果(获益或危害)的干预措施的动物研究:颅脑损伤,出血中的抗纤溶蛋白治疗,急性缺血性中风的溶栓,急性缺血性中风的替利扎扎,产前皮质类固醇预防新生儿呼吸窘迫综合征,并使用双膦酸盐治疗骨质疏松症。 >审查方法提取了有关研究设计,分配隐瞒,随机动物数量,模型类型,干预措施和结果的数据。 >结果 皮质类固醇在治疗颅脑损伤的临床试验中未显示出任何益处,但在动物模型中却显示出了益处(不良功能结局的合并比值比为0.58,95%置信区间为0.41至0.83)。在临床试验中,抗纤维蛋白溶解剂可减少出血,但在动物模型中数据尚无定论。溶栓可改善缺血性卒中患者的预后。在动物模型中,组织纤溶酶原激活剂将梗塞体积减少了24%(95%置信区间为20%至28%),并将神经行为评分提高了23%(17%至29%)。 Tirilazad与缺血性中风患者的预后较差有关。在动物模型中,替拉扎德将梗死面积减少了29%(21%至37%),并将神经行为评分提高了48%(29%至67%)。产前皮质类固醇降低了新生儿的呼吸窘迫和死亡率,而在动物模型中,呼吸窘迫有所减轻,但对死亡率的影响尚无定论(优势比4.2,95%置信区间0.85至20.9)。双膦酸盐可增加骨质疏松症患者的骨矿物质密度。在动物模型中,与安慰剂相比,双膦酸盐阿仑膦酸盐使髋部区域的综合结果使骨矿物质密度增加了11.0%(95%置信区间为9.2%至12.9%)。腰椎的相应治疗效果为8.5%(5.8%至11.2%),前臂(仅狒狒)的综合结果为1.7%(-1.4%至4.7%)。 >结论 动物研究与人类研究之间的不一致可能是由于偏见或动物模型无法充分模仿临床疾病所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号